Hofseth BioCare's ProGo® Bioactive Peptides Show Multi-Target Effects on Healthy Ageing in Peer-Reviewed Clinical Study
核心洞察
A new peer-reviewed clinical study published in Biomedicines demonstrates that ProGo® Bioactive Peptides (搜索) can simultaneously influence multiple biological drivers of healthy ageing, including iron metabolism, inflammation, glucose control, and body composition.
The study found that a single daily supplement of ProGo® produced effects not observed with a protein-matched comparator, suggesting unique bioactive properties beyond standard protein supplementation.
Hofseth BioCare ASA has released a companion white paper summarizing the clinical findings, while ProGo® was recently named winner in the Healthy Aging category at the 2025 NutraIngredients-USA Awards.
A newly published peer-reviewed clinical study has demonstrated that ProGo® Bioactive Peptides (搜索), developed by Hofseth BioCare ASA, can simultaneously modulate several key biological drivers of healthy ageing — effects that were not replicated by a protein-matched comparator. The findings, published in the journal Biomedicines, position the salmon-derived peptide supplement as a potential multi-target intervention in the healthy ageing and metabolic health space.
The study represents what Hofseth BioCare describes as a "thought-provoking first step" in understanding how a single daily supplement may influence interconnected physiological systems central to the ageing process.
Dr. Crawford Currie, Head of Medical R&D at Hofseth BioCare ASA, characterized the significance of the findings: "This study is a thought-provoking first step, showing that a single, simple daily supplement can move several of the biological drivers of healthy ageing at once — iron metabolism, inflammation, glucose control and body composition — in a way a protein-matched comparator did not. We look forward to confirming these signals in larger and longer studies."
The clinical data indicate that ProGo® exerted measurable effects across four distinct biological domains: iron metabolism, inflammatory markers, glucose regulation, and body composition parameters. The divergence from a protein-matched comparator suggests that the observed benefits are attributable to the specific bioactive peptide profile of ProGo® rather than general protein supplementation.
Alongside the Biomedicines publication, Hofseth BioCare is releasing a white paper titled "ProGo® – the Science of Healthy Ageing & Metabolic Health," which translates the clinical findings for a broader, non-specialist audience.
ProGo® Bioactive Peptides (搜索) have gained recognition within the nutraceutical industry, having been named winner in the Healthy Aging category at the 2025 NutraIngredients-USA Awards. The product is also acknowledged for its metabolic health credentials, reinforcing its positioning in the healthy ageing category.
The company has indicated that further investigation in larger and longer-duration studies will be necessary to confirm and extend the signals observed in this initial clinical work.